# Microbiome Therapeutics Sector

Canonical URL: https://biopharmsignal.com/sector/microbiome-therapeutics

Microbiome Therapeutics includes companies developing live biotherapeutics, bacterial consortia, or microbiome-derived approaches to treat disease. These programs are often pursued in GI, immunology, infectious disease, and broader metabolic settings.

Companies currently grouped under Microbiome Therapeutics: 3

## Recent Sector News

- 2026-05-28 20:05 EST — ASMB — [Assembly Biosciences Announces Upcoming Investor Conference Presentations](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-upcoming-investor-conference-presentations) — Source: Assembly Biosciences
- 2026-05-26 20:05 EST — ASMB — [Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-the-closing-of-its-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares) — Source: Assembly Biosciences
- 2026-05-22 11:05 EST — ASMB — [Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants) — Source: Assembly Biosciences
- 2026-05-22 11:00 EST — ASMB — [Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases](https://biopharmsignal.com/news/ASMB/assembly-biosciences-announces-expansion-of-abi-6250-clinical-development-into-cholestatic-liver-diseases) — Source: Assembly Biosciences
- 2026-05-13 06:00 EST — ASMB — [Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026](https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-topline-phase-1a-data-on-hepatitis-delta-virus-entry-inhibitor-abi-6250-at-the-easl-congress-2026) — Source: Assembly Biosciences
- 2026-05-12 11:00 EST — MCRB — [Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-h-c-wainwright-4th-annual-bioconnect-investor-conference) — Source: Seres Therapeutics
- 2026-05-11 12:00 EST — ASMB — [Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference](https://biopharmsignal.com/news/ASMB/assembly-biosciences-to-present-at-the-bofa-securities-2026-global-health-care-conference) — Source: Assembly Biosciences
- 2026-05-07 20:00 EST — ASMB — [Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights](https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-first-quarter-2026-financial-results-and-recent-highlights) — Source: Assembly Biosciences
- 2026-05-05 11:00 EST — MCRB — [Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Seres Therapeutics
- 2026-05-04 11:00 EST — MCRB — [Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease](https://biopharmsignal.com/news/MCRB/seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic-candidate-for-inflammatory-bowel-disease) — Source: Seres Therapeutics
- 2026-04-20 11:00 EST — MCRB — [Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026](https://biopharmsignal.com/news/MCRB/seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026) — Source: Seres Therapeutics
- 2026-04-09 12:00 EST — ASMB — [Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026](https://biopharmsignal.com/news/ASMB/assembly-biosciences-highlights-presentations-on-positive-phase-1b-data-for-abi-5366-and-abi-1179-in-recurrent-genital-herpes-at-escmid-global-2026) — Source: Assembly Biosciences
- 2026-04-09 11:00 EST — MCRB — [Seres Therapeutics to Present at CARB-X Investor Day](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-present-at-carb-x-investor-day) — Source: Seres Therapeutics
- 2026-03-19 20:05 EST — ASMB — [Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights](https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-year-end-2025-financial-results-and-recent-highlights) — Source: Assembly Biosciences
- 2026-03-12 11:00 EST — MCRB — [Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates) — Source: Seres Therapeutics
- 2026-03-02 21:05 EST — MCRB — [Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates](https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-appointment-of-richard-n-kender-as-executive-chair-and-interim-ceo-provides-business-updates) — Source: Seres Therapeutics
- 2026-02-12 12:00 EST — MCRB — [Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases](https://biopharmsignal.com/news/MCRB/seres-provides-program-and-corporate-updates-and-prioritizes-emerging-programs-in-inflammatory-and-immune-diseases) — Source: Seres Therapeutics
- 2026-01-06 12:00 EST — MCRB — [Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy](https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-publications-in-nature-medicine-and-journal-of-infectious-diseases-highlighting-vowsttm-mechanism-of-action-and-supporting-broader-live-biotherapeutic-strategy) — Source: Seres Therapeutics
- 2025-12-22 13:00 EST — ASMB — [Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes](https://biopharmsignal.com/news/ASMB/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes) — Source: Assembly Biosciences
- 2025-12-08 21:05 EST — ASMB — [Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes](https://biopharmsignal.com/news/ASMB/assembly-biosciences-reports-positive-interim-results-from-phase-1b-clinical-studies-of-long-acting-helicase-primase-inhibitor-candidates-abi-1179-and-abi-5366-showing-reductions-in-viral-shedding-rate-and-virologically-confirmed-genital-lesion-rate-in-recurrent-genital-herpes) — Source: Assembly Biosciences

## Companies

- [ASMB](https://biopharmsignal.com/company/ASMB) — Assembly Biosciences
- [FNCH](https://biopharmsignal.com/company/FNCH) — Finch Therapeutics
- [MCRB](https://biopharmsignal.com/company/MCRB) — Seres Therapeutics